… Disease Symptoms That Can Show Up Decades Before a Diagnosis,” freelance science writer Meeri Kim examines the strides researchers have made over the past two decades in … Advisor, Rachel Dolhun, MD, DipABLM , who highlights early warning signs that are often overlooked but can …

… The Research Alliances Intern will focus on analyzing the … Now About Us: The Michael J. Fox Foundation for Parkinson’s Research (MJFF) was founded in 2000 with one clear … organization. Since inception, MJFF has quickly grown into the largest nonprofit funder of Parkinson’s disease …

… of prasinezumab announced this week that the drug is moving into the critical, Phase III stage of clinical trials. If … of people — usually in the thousands. During this trial, researchers gauge a drug’s effectiveness, side effects and … testing following two Phase II trials that demonstrated early signs of promise. The PADOVA trial tested the drug in …

… Parkinson’s disease (PD) is difficult to diagnose early and to distinguish from related synucleinopathies such … grounded, patient-level biomarkers for improved diagnosis, prognosis, and precision treatment. Hypothesis: … deployable blood-based assays, and integrating the markers into clinical trials to improve diagnosis, patient …

… for diagnostic applications in PD patients. Impact on Diagnosis/Treatment of Parkinson’s disease: We expect that … SAA. First, we will generate a digital platform for early and accurate diagnosis and monitoring of PD patients. … is successful, we will provide a simple to use tool kit to researchers and clinicians with the potential to be used as …

… About Us:  The Michael J. Fox Foundation for Parkinson’s Research (MJFF) was founded in 2000 with a single defined … triple-pronged, singularly-defined strategy towards disease research enables a dynamic, motivated, and young organization. MJFF has quickly grown into the largest global funder of Parkinson’s disease …